J&J, Bristol Myers Squibb lose Medicare drug price talks challenges

Jonathan Raa | Nurphoto | Getty Images A federal judge in New Jersey on Monday rejected Johnson & Johnson and Bristol Myers Squibb‘s legal challenges to the Biden administration’s Medicare drug price negotiations, ruling that the program is constitutional.  The decision is another win for the Biden administration in a bitter legal fight with several … Read more

Bristol Myers Squibb (BMY) earnings Q1 2024

The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, US, on Wednesday, Dec. 27, 2023.  Adam Glanzman | Bloomberg | Getty Images Bristol Myers Squibb on Thursday reported first-quarter revenue that topped expectations as its blockbuster blood thinner Eliquis and several new drugs posted sales growth. But the pharmaceutical company … Read more

These are the top 5 companies to work for in India, says LinkedIn

These are the 2024 top companies in India, according to LinkedIn. Deepak Sethi | E+ | Getty Images LinkedIn has released its eighth annual list of top companies to work for in India, and companies that prioritized its employees’ experience and growth dominated this year’s ranking. From mass layoffs to the adoption of generative AI, … Read more

J&J cell therapy gains edge over Bristol Myers rival

Jonathan Raa | Nurphoto | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Hi folks! Two competing cell therapies from Bristol Myers Squibb and Johnson & Johnson both got good news from the Food and Drug Administration on Friday.  But J&J’s drug is … Read more

Medicare drug price negotiations: Judge rejects AstraZeneca challenge

Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services (HHS) building on October 06, 2022 in Washington, DC. Anna Moneymaker | Getty Images A federal judge on Friday rejected AstraZeneca‘s legal challenge to Medicare’s new power to negotiate the prices of certain costly prescription drugs … Read more

Medicare drug price negotiations: Judge tosses PhRMA lawsuit

Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services (HHS) building on October 06, 2022 in Washington, DC. Anna Moneymaker | Getty Images A federal judge on Monday dismissed a lawsuit brought by a major pharmaceutical industry lobbying group and two other organizations that challenged … Read more

Merck, J&J, Bristol Myers Squibb CEOs face Senate drug price hearing

Sen. Bernie Sanders, left, appears at a news conference with Sen. Ed Markey on issuing subpoenas for pharmaceutical company CEOs to testify regarding drug prices, in the Capitol, Jan. 25, 2024. Bill Clark | Cq-roll Call, Inc. | Getty Images Senators will question the CEOs of Johnson & Johnson, Merck and Bristol Myers Squibb on … Read more

Fourth-quarter earnings shaping up to be the best of 2023

Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., February 1, 2024.  Brendan McDermid | Reuters Here’s how big of a surprise corporate profits have been this earnings season: the fourth-quarter is now shaping up to be the best of 2023. Despite ongoing macroeconomic concerns that have … Read more

Bristol Myers Squibb (BMY) Q4 earnings report 2023

Bristol Myers Squibb reported quarterly earnings and revenue that topped expectations on Friday as its portfolio of new drugs posted strong sales growth.  Here’s what the company reported for the fourth quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG, formerly known as Refinitiv: Earnings per share: $1.70 … Read more

J&J, Merck and Bristol Myers Squibb in the hot seat

Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com.  Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks … Read more